Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Patrick Eulitt (NPI 1447677489)

Field	Value
Entity Type	Individual
Organization	Patrick Eulitt
Address	10107 Ridgegate Pkwy Ste 200
City	Lone Tree
State	CO
ZIP	80124
Taxonomy	Medical Oncology Physician
NPI Enumerated	March 27, 2014

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the datasets on file: Total Medicare revenue is $2.4M while Medicaid revenue is none, indicating no Medicaid billing on file and a practice profile driven almost entirely by Medicare reimbursement. Analysts should treat Medicare as the dominant payer when assessing this clinician’s commercial reach, network value, and population served.

Revenue is highly concentrated in a small set of Medicare codes: the precomputed top 3 Medicare codes by revenue account for 69.3% of this provider's total Medicare revenue, with J9271 at $946K (39.8%), J1930 at $430.3K (18.1%), and 78815 at $270.3K (11.4%). This concentration means changes in utilization, pricing, or coverage for those specific services would materially affect practice revenue.

The code mix and top revenue drivers indicate an infusion‑focused medical oncology practice: J9271 (pembrolizumab) and J1930 (lanreotide) are the two largest revenue sources and together with high‑paid imaging via 78815 (PET/CT) point to a service line centered on oncology drug administration and tumor staging/monitoring. The presence of multiple chemotherapy administration and add‑on codes (96413, 96365, 96417) further supports an active infusion/chemotherapy delivery operation rather than a pure consultative practice.

Competitive standing varies by code: for J1930 the provider ranks #5 of 56 nationally (93th percentile) which places them among the heavier national utilizers for that drug despite the dataset labeling the volume as "typical, unremarkable." For J9271 the provider ranks #308 of 1841 (83th percentile) and for 78815 ranks #926 of 6566 (86th percentile), both described as "typical, unremarkable volume," showing above‑median activity on these high‑revenue items but not dominant market share. Conversely, use of J9144 (daratumumab) is relatively lower versus peers (rank #386 of 615, 36th percentile, "typical, unremarkable volume"), indicating selective utilization across expensive oncology agents.

The practice incorporates newer diagnostic radiopharmaceuticals but at modest levels: A9595 (piflufolastat f-18) contributes $92.6K (3.9% of Medicare revenue) and ranks #291 of 528 (45th percentile, "typical, unremarkable volume"), while A9587 (gallium ga-68 dotatate) contributes $56K (2.4%) and ranks #60 of 77 (22th percentile, "typical, unremarkable volume"). These entries suggest adoption of advanced PET tracers for specific indications, but not broad or outsized use relative to national peers.

Biosimilars and supportive care agents appear in the mix, indicating cost management and adherence to contemporary oncology workflows: Q5118 (bevacizumab biosimilar) accounts for $35.4K (1.5%, rank #96 of 161, 40th percentile) and Q5122 (pegfilgrastim biosimilar) accounts for $28.2K (1.2%, rank #134 of 239, 39th percentile). The presence of these biosimilars alongside branded agents suggests the practice uses a blended drug procurement strategy rather than exclusively branded products.

Visit and inpatient E/M activity is present but secondary to drug and imaging revenue: 99214 (255 claims, $23.7K, 75th percentile, "typical, unremarkable volume") and 99215 (139 claims, $18.6K, 86th percentile, "typical, unremarkable volume") show routine outpatient evaluation and management volume consistent with ongoing follow‑up of established oncology patients. Overall, clinical visit revenue is modest relative to high‑value injectable therapies and diagnostic imaging in this Medicare profile.

Operational tenure is established: the provider’s NPI was enumerated on 2014-03-27 (~12 years ago), indicating roughly a decade of presence in Medicare billing data which supports trend analysis and peer benchmarking over a multi‑year period. This length of enumeration combined with concentrated revenue streams makes the provider a stable, Medicare‑focused oncology practice for payer/provider analysts to evaluate for network contracting and utilization management initiatives.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

67 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,000	$40	$946K
J1930	Injection, lanreotide, 1 mg	9,780	$40	$430.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	220	$1,220	$270.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,660	$40	$253.1K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	200	$460	$92.6K
A9587	Gallium ga-68, dotatate, diagnostic, 0.1 millicurie	290	$190	$56K
J0897	Injection, denosumab, 1 mg	3,060	$20	$55.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$110	$46K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	1,610	$20	$35.4K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	30	$1,220	$34.2K

Showing 1–10 of 67

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Patrick Eulitt — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

67 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	40	10,700	$40	$520.5K
J9144	17	20	7,560	$40	$354.8K
J1930	1	10	5,420	$40	$253.1K
A9595	14	20	220	$540	$141.1K
J0897	64	140	2,580	$20	$68.8K
78815	16	120	60	$540	$58.9K
Q5118	2	10	2,520	$20	$56.3K
A9587	3	10	290	$120	$48.9K
Q5122	3	10	320	$90	$30.7K
J3490	31	60	50	$290	$23.1K

Showing 1–10 of 67

Related Providers

Other providers that share a Tax Identification Number (TIN) with Patrick Eulitt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
John Burke	CO	Hematology & Oncology Physician	$2.6M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Patrick Eulitt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Cochlear Americas	CO	Durable Medical Equipment & Medical Supplies	$27.4M	$134.9M
Home Medical Supplies, Inc.	CO	Durable Medical Equipment & Medical Supplies	$0	$10.1M
Mountain View Pain Specialists	CO	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$0	$9.9M
Lone Tree Surgery Center, LLC	CO	Ambulatory Surgical Clinic/Center	$2.3M	$20.8K
Insight Surgery Center, LLC	CO	Ambulatory Surgical Clinic/Center	$1.4M	$79.2K
The Surgery Center At Lone Tree, LLC	CO	Ambulatory Surgical Clinic/Center	$572.7K	$704.7K
Colorado Urologic Surgery Center, LLC	CO	Ambulatory Surgical Clinic/Center	$950.6K	$17.3K
Denver Cyberknife, LLC	CO	Radiation Oncology Clinic/Center	$805.8K	$0
Healthone Ridge View Endoscopy Center, LLC	CO	Ambulatory Surgical Clinic/Center	$670.4K	$32K
Robert Jotte	CO	Hematology & Oncology Physician	$702.1K	$0

Patrick Eulitt — Billing Profile & Reimbursement Data

Sign up for Patrick Eulitt — Billing Profile & Reimbursement Data policy alerts

Patrick Eulitt — Billing Profile & Reimbursement Data

Sign up for Patrick Eulitt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References